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Resumo
Os grafos de conhecimento biomédicos são cruciais para sustentar aplicações em grandes quan-
tidades de dados nas ciências da vida e saúde. Uma das aplicações mais comuns dos grafos
de conhecimento nas ciências da vida é o apoio à comparação de entidades no grafo por meio
das suas descrições ontológicas. Estas descrições suportam o cálculo da semelhança semântica
entre duas entidades, e encontrar as suas semelhanças e diferenças é uma técnica fundamental
para diversas aplicações, desde a previsão de interações proteína-proteína até à descoberta de
associações entre doenças e genes, a previsão da localização celular de proteínas, entre outros.
Na última década, houve um esforço considerável no desenvolvimento de medidas de semelhança
semântica para grafos de conhecimento biomédico mas, até agora, a investigação nessa área tem-
se concentrado na comparação de conjuntos de entidades relativamente pequenos. Dada a diversa
gama de aplicações para medidas de semelhança semântica, é essencial apoiar a avaliação em
grande escala destas medidas. No entanto, fazê-lo não é trivial, uma vez que não há um padrão-
ouro para a semelhança de entidades biológicas. Uma solução possível é comparar estas medidas
com outras medidas ou proxies de semelhança. As entidades biológicas podem ser comparadas
através de diferentes ângulos, por exemplo, a semelhança de sequência e estrutural de duas
proteínas ou as vias metabólicas afetadas por duas doenças. Estas medidas estão relacionadas
com as características relevantes das entidades, portanto podem ajudar a compreender como é
que as abordagens de semelhança semântica capturam a semelhança das entidades.
O objetivo deste trabalho é desenvolver um benchmark, composto por data sets e métodos
de avaliação automatizados. Este benchmark deve sustentar a avaliação em grande escala de
medidas de semelhança semântica para entidades biológicas, com base na sua correlação com
diferentes propriedades das entidades.
Para atingir este objetivo, uma metodologia para o desenvolvimento de data sets de referência
para semelhança semântica foi desenvolvida e aplicada a dois grafos de conhecimento: proteínas
anotadas com a Gene Ontology e genes anotados com a Human Phenotype Ontology. Este bench-
mark explora proxies de semelhança com base na semelhança de sequência, função molecular
e interações de proteínas e semelhança de genes baseada em fenótipos, e fornece cálculos de
semelhança semântica com medidas representativas do estado da arte, para uma avaliação com-
parativa. Isto resultou num benchmark composto por uma coleção de 21 data sets de referência
com tamanhos variados, cobrindo quatro espécies e diferentes níveis de anotação das entidades,
e técnicas de avaliação ajustadas aos data sets.
Palavras Chave: Semelhança semântica, Grafos de conhecimento, Benchmark.
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Abstract
Biomedical knowledge graphs are crucial to support data intensive applications in the life sciences
and healthcare. One of the most common applications of knowledge graphs in the life sciences is
to support the comparison of entities in the graph through their ontological descriptions. These
descriptions support the calculation of semantic similarity between two entities, and finding
their similarities and differences is a cornerstone technique for several applications, ranging from
prediction of protein-protein interactions to the discovering of associations between diseases and
genes, the prediction of cellular localization of proteins, among others.
In the last decade there has been a considerable effort in developing semantic similarity mea-
sures for biomedical knowledge graphs, but the research in this area has so far focused on the
comparison of relatively small sets of entities. Given the wide range of applications for seman-
tic similarity measures, it is essential to support the large-scale evaluation of these measures.
However, this is not trivial since there is no gold standard for biological entity similarity. One
possible solution is to compare these measures to other measures or proxies of similarity. Biolog-
ical entities can be compared through different lenses, for instance the sequence and structural
similarity of two proteins or the metabolic pathways affected by two diseases. These measures
relate to relevant characteristics of the underlying entities, so they can help to understand how
well semantic similarity approaches capture entity similarity.
The goal of this work is to develop a benchmark for semantic similarity measures, composed of
data sets and automated evaluation methods. This benchmark should support the large-scale
evaluation of semantic similarity measures for biomedical entities, based on their correlation to
different properties of biological entities.
To achieve this goal, a methodology for the development of benchmark data sets for semantic
similarity was developed and applied to two knowledge graphs: proteins annotated with the
Gene Ontology and genes annotated with the Human Phenotype Ontology. This benchmark
explores proxies of similarity calculated based on protein sequence similarity, protein molecu-
lar function similarity, protein-protein interactions and phenotype-based gene similarity, and
provides semantic similarity computations with state-of-the-art representative measures, for a
comparative evaluation of the measures. This resulted in a benchmark made up of a collection
of 21 benchmark data sets with varying sizes, covering four different species at different levels
of annotation completion and evaluation techniques fitted to the data sets characteristics.
Keywords: Semantic Similarity, Knowledge Graphs, Benchmark.
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Resumo Alargado
Atualmente, com o desenvolvimento constante de tecnologias, novas ou pré-existentes, estamos
perante um crescimento nunca visto na quantidade de dados produzidos pelos diversos domínios
de conhecimento humano. Isto trouxe consigo desafios em lidar com o tamanho, complexidade
e diversidade dos dados. Um domínio principalmente responsável por esta explosão de dados,
acompanhada pela incapacidade de os processar, foi o domínio das ciências da vida. As di-
versas tecnologias utilizadas em investigação nas áreas da genómica e proteómica produzem, a
uma velocidade superior à de processamento, grandes quantidades de dados complexos sobre a
função, regulação e interação de genes e proteínas. O processamento e integração destes dados é
fundamental para tarefas como a associação de genes e proteínas às doenças que causam, entre
outras aplicações.
O domínio das ciências da vida é composto por áreas diversas que utilizam diferentes e com-
plexas nomenclaturas para expressar o conhecimento que, após processamento dos dados para
a sua extração, é guardado sob a forma de linguagem natural. Esta é ainda, aliás, a forma
principal de comunicação em ciência, pela divulgação das diversas descobertas feitas no mundo
da investigação através da publicação de artigos científicos. No entanto, o crescimento exponen-
cial da quantidade de dados nesta área tornou insustentável a utilização de linguagem natural
como a única forma de representação de conhecimento e impulsionou a pesquisa por uma forma
estruturada de representação do conhecimento que permitisse a compreensão deste tanto por
humanos como por computadores.
As ontologias são um exemplo deste tipo de representações. Estas representam, sob a forma
de grafo, os conceitos dentro de um domínio de conhecimento de forma a que cada conceito
esteja definido precisamente e através de relações, hierárquicas ou não, com outros conceitos. A
capacidade das ontologias de fornecerem uma descrição estruturada das entidades foi o principal
motivo que levou à adoção das ontologias para a caracterização de entidades, e à sua proliferação
dentro do domínio biomédico e não só.
A caracterização de entidades com ontologias, através do processo de anotação semântica, per-
mite a representação do conhecimento existente sobre estas na forma de um grafo, apelidado de
grafo de conhecimento. Os grafos de conhecimento, associados a diferentes técnicas de apren-
dizagem automática que os explorem, abrem a possibilidade da mineração do conhecimento de
domínios complexos, como o biomédico. Ao representarmos várias entidades no mesmo grafo
de conhecimento podemos, por exemplo, computar a semelhança semântica entre duas enti-
dades, com algoritmos que explorem e comparem as descrições ontológicas de cada entidade. A
semelhança semântica é uma medida da proximidade de significado entre duas entidades, cujo
significado é definido pela ontologia que contextualiza o grafo de conhecimento. O cálculo da
semelhança semântica suporta a realização de tarefas como integração de dados heterogéneos,
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estabelecimento de ligações ou correspondências entre entidades, comparação e agrupamento de
entidades ou geração de recomendações. No domínio biomédico, em particular, a semelhança
semântica já foi aplicada à previsão de interações proteína-proteína, da associação entre genes
e doenças ou de interações fármaco-alvo.
A popularidade destas medidas impulsionou o seu desenvolvimento e, atualmente, existem di-
versas medidas de semelhança semântica, cada uma com as suas características, e desenvolvidas
em diferentes contextos. Esta variedade, tanto em termos de medidas de semelhança semântica
como de aplicações para as mesmas, torna fundamental a determinação da melhor medida para
cada aplicação. No entanto, esta avaliação não é trivial, uma vez que não existe um padrão-
ouro para semelhança entre entidades biológicas e, uma vez que cada medida define a noção
de semelhança de forma diferente, determinar qual é a melhor abordagem torna-se uma decisão
parcial.
A avaliação de medidas de semelhança semântica e a escolha da melhor medida para cada apli-
cação é ainda um processo em aberto. Uma vez que a maioria dos estudos realizados neste
sentido usam apenas uma medida ou aplicam o estudo a um pequeno, e controlado, conjunto
de dados, os seus resultados não são diretamente comparáveis, tornando ainda mais difícil a
determinação da melhor medida para a aplicação em questão. Uma vez que não existe nenhuma
formal universal de determinar a semelhança entre duas entidades biológicas, uma abordagem
possível é o uso de aproximações de semelhança biológica como medida de avaliação das medi-
das de semelhança semântica. Estas aproximações de semelhança são medidas que capturam a
semelhança biológica das entidades através de diferentes ângulos. Por exemplo, ao determinar
a semelhança de duas proteínas através da sua sequência, estrutura, função, vias metabólicas e
interações estamos a considerar diferentes planos através dos quais um par de proteínas pode
ser semelhante ou diferente. Ao utilizarmos estas medidas, estamos a abordar diferentes car-
acterísticas das proteínas, que podem ser utilizadas para avaliar como é que cada medida de
semelhança captura a semelhança dessas entidades através das diferentes aproximações.
O objetivo desta dissertação é desenvolver um benchmark, composto por data sets e métodos de
avaliação automatizados, que sustentem a avaliação em grande escala e diretamente comparável
de medidas de semelhança semântica para entidades biomédicas, com base na sua correlação
com diferentes propriedades de entidades biológicas.
Para atingir este objetivo, uma metodologia para o desenvolvimento de conjuntos de data sets de
referência para semelhança semântica foi desenvolvida. Esta metodologia é composta por quatro
passos, nomeadamente seleção de entidades para os data sets, formação de pares de entidades
para os data sets, seleção e computação de medidas de semelhança semântica e biológica entre os
pares de entidades e seleção e implementação de técnicas de avaliação das medidas de semelhança
semântica. Os primeiros três passos desta metodologia garantem o desenvolvimento de data sets
de referência que seguem as diretrizes para data sets de referência de qualidade e o último passo
da metodologia, permite que, com base nos data sets desenvolvidos, sejam realizados estudos
sistemáticos para a avaliação de medidas de semelhança semântica em grande escala.
A metodologia desenvolvida foi aplicada a dois grafos de conhecimento: proteínas anotadas
com a Gene Ontology e genes anotados com a Human Phenotype Ontology. Este benchmark
explora aproximações de semelhança calculadas com base na semelhança de sequência de pro-
teínas, semelhança de função molecular de proteínas, interações proteína-proteína e semelhança
de genes baseada em fenótipos, e fornece cálculos de semelhança semântica com medidas repre-
sentativas do estado da arte, para uma avaliação comparativa das medidas. Isto resultou num
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benchmark composto por uma coleção de 21 data sets de referência com tamanhos variados,
cobrindo entidades de quatro espécies diferentes, em diferentes níveis de anotação e incluindo
ainda técnicas de avaliação ajustadas às características dos data sets. Dos 21 data sets, 20 são
data sets com pares de proteínas anotadas com a Gene Ontology, uma vez que esta é a ontologia
que é a base de mais medidas de semelhança semântica. Estes data sets estão divididos em duas
coleções, uma baseada em função molecular e a outra em interações proteína-proteína. Para
estes data sets, o benchmark suporta não só o cálculo da correlação de semelhança semântica
com cada uma das aproximações de semelhança disponíveis para cada data set como também,
para os data sets de interação proteína-proteína, avaliação do impacto das medidas de semel-
hança semântica na previsão destas interações. O data set composto por genes anotados com
a Human Phenotype Ontology contém pares de genes humanos que suportam a avaliação de
medidas de semelhança semântica com base na relação destas medidas com a semelhança de
fenótipos em que os genes estão envolvidos.
No futuro, o benchmark pode ser atualizado através de melhoramentos nos atuais componentes
ou introdução de novos. Este tipo de atualizações podem incluir atualização dos data sets exis-
tentes, através de introdução de novas medidas de semelhança semântica ou biológica, ou novas
técnicas de avaliação, expansão dos data sets baseados nos grafos de conhecimento utilizados
para outro tipo de pares de entidades ou inclusão de novos data sets com pares de entidades
anotados com outras ontologias biomédicas. Mais ainda, a metodologia desenvolvida nesta dis-
sertação pode ser aplicada a qualquer domínio onde uma aproximação de semelhança possa ser
implementada, tornando o desenvolvimento de benchmarks análogos fora do domínio biomédico
uma possibilidade.
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Chapter 1
Introduction
Nowadays, with the non-stop improvement of several technologies and development of new ones,
we are witnessing an unprecedented growth in the size of data produced by nearly all domains
of human endeavour. That brought with it new challenges in handling the size, complexity and
diversity of data. One of the domains where this data deluge has altered nearly every aspect of
its workings is the life sciences. High throughput techniques in genomics and proteomics produce
large amounts of data about the function, regulation and interaction of genes and proteins, and
their integration with clinical research has helped link thousands of genes and proteins to their
related diseases, among other tasks (T. P. [2011]).
The biomedical domain is one of complex and volatile data where the knowledge, after its
extraction from data analysis, is usually recorded in natural language in scientific publications.
However, given the exponential growth of already large quantities of data and associated knowl-
edge, this was an unsustainable form of representation. This knowledge needs to be stored in a
computationally amenable fashion, making data and knowledge understandable by both humans
and computers (Stevens et al. [2004]).
An example of these types of representations are ontologies. Since the early 2000’s, biomedi-
cal ontologies have been increasingly used to annotate data, which has resulted in a proliferation
of ontologies (there more than 850 currently stored in BioPortal1 (Whetzel et al. [2011a])) and
ontology annotated data sets, many available as linked open data (e.g. Bio2RDF2(Belleau et al.
[2008])). The creation of these resources, as is also the case of more general purpose knowledge
graphs (KGs) such as DBpedia (Lehmann et al. [2015]), has been the stepping stone to achieve
a structured and linked representation of the knowledge throughout different domains, a web of
data.
In the biomedical domain, the ability to compare entities, such as genes, cells, organisms,
populations or species, and finding their similarities and differences, is essential to support
scientific inquiry. While comparing the sequences of two genes or the structures of two proteins
can be achieved directly, because both have objective representations and measurable properties,
the comparison of more complex aspects of biological entities, such as their function, is not
straightforward.
1https://bioportal.bioontology.org/
2https://bio2rdf.org/
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Ontologies provide mechanisms of objective representation that support measurement of
these more complex aspects. Thus, the representation of entities in KGs, coupled with the
development of machine learning techniques able to explore them, opens unparalleled oppor-
tunities for the mining of complex domains, as the biomedical domain. For instance, having
entities represented in the same KG supports the computation of the similarity between en-
tities, with algorithms that explore ontology features, semantic similarity measures (SSMs).
These are measures of how closely related in meaning two entities are. Depending on the level
of specialization of the ontology used to describe the entities, the spectrum of comparison be-
tween the entities will vary. For instance, the Gene Ontology (GO) is an ontology developed for
the annotation of gene products, that describes these entities regarding three aspects of gene
function: their cellular localization, their function inside the cell and the biological process to
which they contribute to (Ashburner et al. [2000]). Two proteins annotated with the GO that
are compared with a SSM will undergo a more general comparison than being compared via
their structure, sequence or common metabolic pathways.
Several tasks can be supported by these SSMs, such as integration of heterogeneous data,
entity linking or matching, comparison and clustering of entities and generation of recommen-
dations (Harispe et al. [2015]). In fact, computing similarity between instances is an integral
part of many machine learning techniques, both supervised and unsupervised. In the biomedical
domain, semantic similarity (SS) has been successfully applied to such diverse tasks as the pre-
diction of interaction between proteins, of disease-associated genes or of drug-target interaction
(Hoehndorf et al. [2015]). It is worth noting that in these applications similarity is not used to
detect identity, but rather to predict the likelihood of a given entity exhibiting a given property.
There are several measures available (Harispe et al. [2015]) each with its distinguishing
characteristics. Given the variety of approaches and measures for SS, it is fundamental to
determine the best measure for each application scenario. However, there is no gold standard
for similarity between biomedical entities, and a manual assessment of similarity by domain
experts is unfeasible, not only due to the size of the data, but also because each expert is
inherently biased towards a viewpoint of the domain or a particular use case. Furthermore, the
existing measures formalize the notion of similarity in slightly different ways and for that reason
it is not possible to define what the best SSM would be, since it becomes a subjective decision.
Evaluating the reliability of a SSM or determining the best measure for each application
scenario is still an active area of research. Most application studies use only one measure, or
test them in a small and controlled set of data, developed for that study alone. An unsystematic
assessment practice can lead to biases in published results, a phenomenon referred to as the
self-assessment trap (Mangul et al. [2019]). Moreover, the results from these studies are not
directly comparable across them, making it difficult to assess which measure is best for which
purpose.
1.1 Objectives
Because there is no direct way to determine the true functional similarity of two biological
entities, one possible solution is to compare the SSMs to other measures or proxies of similarity.
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In the biomedical domain, entities can be compared through different lenses. For instance we can
compare two genes via their sequence similarity, two proteins via their structural similarity or
two diseases by the metabolic pathways they affect. These similarities do not provide the broad
spectrum comparison that SS supports, but they can be used as measures of similarity at different
levels, since they are known to relate to relevant characteristics of the underlying entities. Thus,
correlating SS with such properties can help us understand how well SS approaches capture
entity similarity.
Moreover, for an accurate assessment of the impact of a SSM in a given task, the measure
should be benchmarked against other SSMs. This means running the same tests for a set of
SSMs and comparatively evaluate their performance under the same conditions. This approach
would tackle the issues previously exposed in the small scale and non-systematic evaluation of
SSMs.
The main goal of this dissertation is to develop a benchmark for SSMs in the biomedical
domain. The benchmark should tackle the following challenges:
• Cover multiple KGs;
• Cover entities of multiple species;
• Consider different types of proxy similarities;
• Include representative state-of-the-art SSMs;
• Provide easy to use performance metrics.
1.2 Contributions
The main contributions of this dissertation are:
1. Development of a methodology for the construction of benchmark data sets for KG-based
SS;
2. Implementation of the developed methodology to the construction of a collection of bench-
mark data sets for SS in the biomedical domain. These data sets include pairs of genes
or proteins, grouped by species (D. melanogaster, E. coli, H. sapiens and S. cerevisiae),
annotated with either the GO or the Human Phenotype Ontology (HPO);
3. Development of a benchmark that supports the proxy-based evaluation of SSMs in biomed-
ical KGs;
4. Availability and accessibility of the data sets and benchmark in an online repository3;
5. Poster paper with the characterization of the benchmark data sets entitled “A Collection
of Benchmark data sets for Knowledge Graph based Similarity in the Biomedical Domain”,
presented at the 17th Extended Semantic Web Conference, online edition, where it was
co-awarded best poster paper;
3https://github.com/liseda-lab/kgsim-benchmark
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6. Submission of an original article entitled “A Collection of Benchmark data sets for Knowl-
edge Graph based Similarity in the Biomedical Domain” to Database: The Journal of
Biological Databases and Curation.
1.3 Document Structure
Additionally to the present introductory chapter, that gives a contextualization for the problem
at hand and proposed solution, this document is structured in six chapters as follows:
• Chapter 2 (Concepts) introduces the basic concepts whose understanding is vital for the
comprehension of this dissertation, namely, the semantic web, ontologies, KGs, SS and
benchmarking.
• Chapter 3 (Related Work) presents recent work developed in the scope of this dissertation.
• Chapter 4 (Methodology) presents the general methodology developed for the construc-
tion of a benchmark for SS.
• Chapter 5 (Building the Benchmark) presents the implementation of the methodology
from Chapter 4 in two KGs for the construction of the benchmark for SS in the biomedical
domain.
• Chapter 6 (Results and Discussion) presents the results from the methodology imple-
mentation and discusses the features of the resulting resource.
• Chapter 7 (Conclusion) discusses the main conclusions of this work, and indicates some
directions for future work.
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Concepts
This chapter introduces the concepts that are vital for the understanding of the work presented
in this dissertation. The concepts in here defined are the Semantic Web and its underlying
components, SS approaches for ontologies and KGs and guidelines to build quality Semantic
Web resources and benchmarks.
2.1 Semantic Web
In Berners-Lee et al. [2001] the Semantic Web is defined as “an extension of the current web
in which information is given well-defined meaning, better enabling computers and people to
work in cooperation”. For it to function, machines must have access to structured and connected
collections of data, defined with a strict vocabulary and a set of rules, so that it can be used to
conduct automated reasoning by Semantic Web tools.
However, data resulting from biomedical research is stored in word, phrase or text format,
and are meaningless for computers that seek to apply reasoning over them. The goal of Semantic
Web research is to allow the vast range of web-accessible information and services to be more
effectively exploited by both humans and automated tools (Horrocks [2008]). Thus, data should
be represented in a formal, structured, machine-readable manner through the process of semantic
annotation. This allows meaning to be assigned to the resources, usually by linking them to an
ontology, creating a KG (Jacob [2005]; Pulido et al. [2006]).
2.1.1 Ontologies
An ontology is a technique used to represent the knowledge about a domain, by modeling its
concepts and the relationships between them (Bodenreider and Stevens [2006]). Ontologies have
two components: classes and properties. A class is a term that refers to a set of entities in a
system (e.g. the class ‘protein’ represents all proteins in the system). Properties establish how
one class relates to another (e.g. ‘protein’ ‘is a’ ‘molecule’, where ‘is a’ defines the relationship
between ‘protein’ and ‘molecule’) (Hoehndorf et al. [2015]). Figure 2.1 shows an excerpt of the
GO, a very successful biomedical ontology.
The relations between classes can be structured in triples, as depicted in Figure 2.2. Each
class or property in an ontology should be identified by a unique Uniform Resource Identifier
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GO:0043229
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GO:0005575
Cellular Component
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part_of
part_of
part_of
Figure 2.1: Excerpt of the GO graph representing the class GO:0005739 “Mitochondrion” and its ances-
tors.
(URI) that is used to identify each component of a triple: subject, predicate and object. The
predicate denotes the relationship that exists between the subject and the object.
GO:0070231
T cell apoptotic process
Subject Object
Predicate
GO:0070227
Lymphocyte apoptotic
process
is_a
Figure 2.2: Structure and example of a triple from the GO. This triple shows the relation between
the class GO:0070321 “T cell apoptotic process” and its ancestor GO:0070227 “Lymphocyte apoptotic
process”.
These triples make up the backbone of an ontology, and different specialized languages can
be used to model them, depending on the requirements and the goals of the applications:
• Resource Description Framework (RDF): RDF is a simple language based on triples
that specify the relation between the subject and the object via the predicate. A set of
RDF triples make up a graph making it possible for RDF to be a valid ontology language,
but a limited one (Horrocks [2008]).
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• Web Ontology Language (OWL): OWL is a vocabulary extension of RDF, but far
more powerful. An OWL ontology consists of a set of axioms of 2 types: Terminology
Box (TBox) and Assertion Box (ABox). TBox axioms serve the purpose of defining an
hierarchy of classes and properties, but also restrictions as the disjointness of two classes
or characteristics of some properties. ABox axioms express facts about specific entities
(e.g. individuals) and are usually not included in an ontology definition (Horrocks [2008]).
• Open Biomedical Ontology (OBO) Flat File: This format attempts to achieve hu-
man readability, ease of parsing, extensibility and minimal redundancy. An OBO docu-
ment’s structure is divided in header and stanzas. While the header serves the purpose
of describing generic information about the ontology (e.g. version) each stanza enclosures
the description and relations of each ontology element (Golbreich et al. [2007]).
In many fields of biomedical research, ontologies play an essential role in tasks such as
knowledge representation or data integration. Their acceptance, and relevance of their use in this
domain, has been responsible by a non-stopping development of new ontologies, accompanied
by the growth of widely used ones in the last years. As of June 2020, Bioportal (Whetzel
et al. [2011b]), “the world’s most comprehensive repository of biomedical ontologies”, stored
over 850 biomedical ontologies, with scopes as diverse as the characterization of gene products
(as is the GO) to phenotypic abnormalities in human diseases (HPO (Köhler et al. [2009]))
or the characterization of drugs (Chemical Entities of Biological Interest (ChEBI))(Hastings
et al. [2016])). Ontologies can sometimes have overlapping domains, as is the case of multiple
anatomy ontologies, whose goal is the enumeration of existing knowledge about the structure of
organisms and their constituting parts. Examples of these ontologies include the Foundational
Model of Anatomy (Rosse and Mejino [2004]) for humans and the Drosophila Anatomy Ontology
(Mesquita da Costa et al. [2013]) for the fruit fly.
2.1.2 Semantic Annotation
Given the abstract nature of ontologies, their statements are true for all entities of a given type,
as opposed to being specific of a certain entity. However, ontologies can be used to describe real-
world entities through the process of semantic annotation. Describing entities with classes from
an ontology allows the assignment of meaning to these entities. Since ontologies are modelled in
a formal and machine readable language, annotating multiple entities with the same ontology
allows for reasoning to be applied to them. Figure 2.3 shows part of the graph formed by using
the GO to annotate a protein. These annotations can be seen as a semantic description of the
protein, since they can be used to, computationally, assign to the protein a meaning.
The process of annotation provides a semantic description of the entities by taking advantage
of the hierarchical representation provided by an ontology that enables computational reasoning.
This is more than an explicit description of the entity, as one would find in a dictionary entry of
a word, as it describes the entities through the classes and their relations to each other. Thus,
the richer the ontology is in relations between classes and the thorough the annotation is, the
better captured the semantic description of the entity will be (Stevens et al. [2004]).
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Figure 2.3: Sub-graph of GO formed by a gene product (Protein P19367) and GO classes. For this gene
product, the classes that best describe it are chosen for its annotation.
2.1.3 Knowledge Graphs
The knowledge provided by linking entities and ontologies can be represented in graph form.
These representations, KGs, are a systematic way to connect the information on entities (e.g.
proteins, genes) to data representations. For this purpose, ontologies provide the context in
which the entities are being represented (Dörpinghaus and Jacobs [2019]).
The nodes of a KG represent ontology classes or entities while edges represent ontology
relations. An example of a portion of a KG is represented in Figure 2.4, contextualized by the
GO and its annotations, where proteins are linked to GO classes and other proteins.
KGs have vast applications in the biomedical domain, based on the ontological descriptions
of the entities. For instance, enrichment analysis can be performed in a group of interacting
proteins to test the hypothesis if a given function is more common in that group of proteins
than in a sample of the same size from the whole system (Hunter [2017]).
2.2 Semantic Similarity
A SSM is a function that, given two ontology classes or two sets of classes describing two
entities, returns a numerical value reflecting the closeness in meaning between them (Pesquita
et al. [2009a]).
The approaches used to quantify SS can be distinguished based on which entities they intend
to compare: there are approaches for comparing two classes and approaches for comparing two
entities annotated with its own set of classes.
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Figure 2.4: Sub-graph of the GO KG illustrating the relations between proteins and GO classes. Proteins
are represented in orange boxes and GO classes in grey boxes.
For comparing classes within an ontology, edge or node-based measures can be employed:
• Edge-based approaches: These measures rely on the number of edges in the graph path
between the two classes, either by calculating the distance between them, or through the
length of the lowest common ancestor of the two classes to the root node. Despite being
intuitive, these measures bear issues with them: they are based on the assumption that all
edges at the same level of the ontology correspond to the same semantic distance between
classes, and that edges and nodes are uniformly distributed throughout the graph. These
problems make edge-based approaches rarely used in the biomedical domain.
• Node-based approaches: These measures depend on the properties of the classes in-
volved. They typically rely on the information content (IC) of a class, a measure of how
informative or, rather, specific a class is (Pesquita et al. [2009a]). The IC can be calculated
through the graph structure (intrinsic approach) or the number of annotations a class is
used on (extrinsic approach).
To calculate SS for two entities, each annotated with a set of classes, both pairwise and
groupwise approaches can be used (Pesquita et al. [2009a]):
• Pairwise approaches: In these approaches functional similarity between two entities is
assessed by combining the SS between their classes.
• Groupwise approaches: In these approaches set, vector or graph-based measures are
employed.
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GO:0003674
Molecular Function
GO:0005575
Cellular Component
GO:0008150
Biological Process
Protein A Protein B
Figure 2.5: Use of the GO annotations for the calculation of SS between two proteins. Grey-filled circles
are common classes between the two proteins, blue-filled circles are classes that only annotate Protein A,
and orange-filled circles are classes that only annotate Protein B.
From Figure 2.5 we can calculate SS between proteins A and B using a groupwise approach,
by finding the number of classes common to both proteins and dividing it by the total number
of classes annotating both proteins, i.e., sim(A,B) = 624 =
1
4 = 0.25. This is a very simple
tackle on a SS problem, but more sophisticated approaches, combining different strategies for
class and entity similarity, can be employed.
SS has been successfully applied to computationally predict protein–protein interactions
(PPIs), based on their functional similarity, to the diagnosis of diseases, based on phenotypic
similarity, or to the classification of chemicals based on structural similarity (Hoehndorf et al.
[2015]). It is worth noting that in these applications, similarity is not used to detect identity,
but rather to predict the likelihood of a given entity exhibiting a given property.
2.3 Semantic Web Resources
Scientific advancement relies on quality resources that provide the necessary scaffolding to sup-
port scientific publications. Sharing these resources and the best practices that have lead to
their development is crucial to consolidate research material, ensure reproducibility of results
and, in general, gain new scientific insights.
To integrate the data emerging from all different kinds of research and promote reuse of
produced resources, there is a set of guidelines one should follow in their development and
publication, known as the FAIR Guiding Principles (Wilkinson et al. [2016]). The FAIR Guiding
Principles are a set of guidelines for scientific data management and stewardship that apply to
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three types of entities: data (e.g. from gene regulation and expression analysis), metadata (data
for the characterization of a digital object, e.g. the GO as a tool for describing gene products)
and infrastructure (data platform, e.g. UniprotKB (Consortium [2018])). Given the role of
machines in the data to knowledge process, due to the inability of humans to operate at the
scale and speed needed by the size and complexity of scientific data, these principles emphasise
the importance of machine data management with minimal human intervention and state that
these entities should be Findable, Accessible, Interoperable and Reusable:
• Findable: (Meta)data should be easy to find by both users and computers. Data is
assigned an unique identifier (e.g. URI), that should also be used when using metadata
to describe data (e.g. in the annotation process), to clearly state what metadata is being
assigned to each data set and make sure it is described properly.
• Accessible: More than found, data should be accessed. This should be ensured either by
free or authentication/authorization-based access. Metadata should persist even if data is
no longer available.
• Interoperable: The data should be described using a formal representation that allows
for users to use each other’s data. These representations (e.g. ontologies) should also
follow the FAIR principles. Additionally, (meta)data should include cross-references to
other (meta)data, to create as many meaningful links as possible between them and enrich
the knowledge about the data.
• Reusable: Ultimately, the goal of the FAIR principles is to allow data reusability. This
means ensuring that data can be used by others than its creator. For this purpose,
meta(data) should be richly described with relevant attributes that facilitate its reuse
(i.e. usage licence, relevant publications, scope, version, etc).
2.3.1 Benchmarking
In bioinformatics, a benchmarking study consists of a comprehensive evaluation of the relative
performance of existing algorithms targeted at solving the same, or similar, biology problem
(Mangul et al. [2019]).
The wide variety of tools available today, as is the case of SSMs, means that it is often difficult
to choose the most appropriate for a specific problem. Comparative evaluation of the different
methods is a crucial task, not only to select the most suitable method (e.g. more efficient, more
correct, more scalable), but also to evaluate the improvements obtained when a new method is
introduced and to identify the strengths and weaknesses of the different algorithms (Aniba et al.
[2010]).
Similarly to the FAIR guiding principles for data, there are also a few rules to follow when
building trust-worthy benchmarks. These include, but are not limited to, what the benchmark
aims at measuring and how it must do so (Aniba et al. [2010]):
• Relevance: Benchmarks should be adapted to the algorithms they aim at testing. This
means that the evaluating tasks should match the ones the the algorithms are expected
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to handle and should capture different abilities of the algorithms. Furthermore, all tasks
should produce any type of performance measure that can then be used for comparison of
results.
• Solvability: The tasks the algorithms are subjected to should be achievable but not
trivial. This provides an opportunity for systems to show both their capabilities and their
limitations.
• Accessibility: The benchmark should be easy to obtain and to use. To promote the
comparison of results, these need to be publicly available
• Independence: To avoid overfitting, or a bias towards a certain algorithm, the benchmark
tasks should not be based on information achieved with the algortihms under evaluation.
Instead, independent information from other techniques or from human experts should be
used to evaluate the correctness of the results.
• Evolution: The benchmark should not stagnate, to prevent researchers from evolving
their algorithms solely to achieve a good score in the particular set of tests the benchmark
is based on.
These testing and evaluation methods are dependent on data sets, that are used to build
the tests the algorithms will undergo. By comparison of the algorithms results to the existing
knowledge, their performance can be assessed. For that purpose, benchmark data sets with
known and verified outcome are needed.
High-quality benchmark data sets are valuable and may be difficult, laborious and time
consuming to generate. From a point of view of reasonable use of resources it is important to
share such data sets. Moreover, the reuse of the same data set for different studies, can make
them directly comparable, a comparison that would not be reliable otherwise. The criteria for a
quality benchmark data set intersect the FAIR guiding principles and criteria for a trust-worthy
benchmark study, since these studies rely on the knowledge provided by these data sets, and
include the following features (Sarkar et al. [2020]):
• Relevance: The data set should include the necessary features for the chosen evaluation
task, and avoid the inclusion of non-relevant or indirectly related data.
• Representativeness: Representativeness is of special relevance in these data sets. The
data set should provide a balanced cross-section of biomedical entities, cover the event
space as well as possible and be of sufficient size to allow statistical studies. Positive and
negative cases, if applicable, should be included. Additionally, should these data sets be
used for supervised learning applications, these predictors will benefit from learning from
a more general data set. If the cases used for training are particularly biased towards a
feature, the performance of the predictor will be biased as well.
• Non-redundancy: This means excluding overlapping cases within each data set.
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• Experimentally verified cases: Method performance comparisons have to be based on
experimental data. This feature is of special importance, once more, in supervised learning
applications since, if the data is based on another predictor, the evaluation task would be
about the congruence of methods, and not their true performance.
• Reusability: The data sets, and related resources, should be shared, to promote their
use for other research and publications and their direct comparison.
These set of features will be the guidelines followed when developing and applying the
methodology for benchmark construction.
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Related Work
This chapter presents a survey on the work developed in the past years on the scope of this
dissertation, namely SS and its applications and tools for the evaluation of KG-based SSMs.
3.1 Semantic Similarity
The use of SS in the biomedical field has benefited many bioinformatics applications by resorting
to KG-based SSMs.
GO-based SS is the main focus of investigation of SS in this domain and has been the
motivator for the development of several new SSMs. Overall, SS in the GO has been applied
mainly for validating and predicting functions and interactions, and for analysing transcriptomics
and proteomics data. In predicting and validating the function of gene products, these measures
can be combined with other similarity metrics, as structural similarity (Liu et al. [2007]) or
sequence similarity (Yu et al. [2016]; Makrodimitris et al. [2018]) for better results. In PPI
prediction and validation, similarly, SS can be the sole approach (Jain and Bader [2010]; Zhang
et al. [2018]) or be used to improve already existing techniques (Mahdavi and Lin [2007]). Finally,
the role of SS in the analysis of transcriptomics and proteomics data is mainly the improvement
of clustering of co-expressed gene products (Al-Mubaid and Nagar [2008]; Wang et al. [2005];
Kustra and Zagdanski [2006]).
SS using other ontologies can also play an important role in biomedical research. For instance,
the HPO provides comprehensive bioinformatic resources for the analysis of human diseases and
phenotypes (Köhler et al. [2018]). Different SS-based techniques can be used to rank diseases
annotated with the HPO based on how similar they are to several queries of HPO classes (Köhler
et al. [2009]; Gong et al. [2018]). This method allows for the clinical diagnosis of patients, by
finding the most similar disease to their set of symptoms. Similarly, Masino et al. [2014] use SS
and the HPO to predict the disease causing gene in patients. Some SS-based approaches in the
HPO resulted in the development of SSMs (Köhler et al. [2009]; Xue et al. [2019]; Hoehndorf
et al. [2011]).
Another example of an ontology with use in the biomedical domain is ChEBI (Hastings et al.
[2016]). ChEBI is a database and an ontology, that contains information about chemical entites,
where these are classified, within the ontology context, based on their structure and biological
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or chemical role. Despite being scarcer, there are some applications for ChEBI-based SS. For
instance, combining semantic and structural similarity can be used to predict molecular function
(Ferreira and Couto [2010]) or drug repurposing (Tan et al. [2014]).
The popularity and diverse utility of SS led to the development of several SSMs. Tables
3.1 and 3.2, an updated adaptation of the survey in Guzzi et al. [2011], present an overview of
different SSMs, with its original publication and important features.
Table 3.1: Summary of Pairwise SSMs. Columns Class IC, Common Ancestor (MICA), All
Common Ancestors (ACA), Path Length and Class Depth refer to the different features of
SSMs. Column Evaluation Technique describes the context in which each similarity measure
was tested.
Name Reference Class IC MICA ACA
Path
Lenght
Class
Depth
Evaluation Technique
Annotation cosine Bodenreider et al. [2004] No No No No No Associations between classes
BSM Cheol Jeong and Chen [2015] No Yes Yes No Yes Correlation with sequence; Functional clustering
EISI Zhang and Lai [2014] Yes No No No No Intra-pathway similarity
G-SESAME Wang et al. [2007] No No Yes Yes No Gene Clustering
GraSM Couto et al. [2007] Yes Yes No No No Correlation with MF
GOGO Zhao and Wang [2018] Yes No Yes No Yes Gene Clustering
HRSS Wu et al. [2013] Yes Yes No Yes Yes Correlation with EC, MF and sequence
Jiang and Conarth Jiang and Conrath [1997] Yes Yes No No No Correlation with human perception
Lin Lin [1998] Yes Yes No No No Correlation with MF
Othman Othman et al. [2008] Yes Yes No Yes Yes Annotation prediction
PS or PK-TS Pekar and Staab [2002] No Yes No Yes Yes Classification of synonyms
Resnik Resnik [1995] Yes Yes No No No Correlation with human perception
RSS Wu et al. [2005] No Yes No Yes Yes MF prediction
SB-TS Yu et al. [2005] No No No No Yes MF prediction
SimDEF Pesaranghader et al. [2015] No No No No No Correlation with sequence and gene expression
SimIC Li et al. [2010] Yes Yes No No No PPI prediction
SPBHM Bandyopadhyay and Mallick [2013] No No Yes Yes No PPI prediction; Correlation with gene expression
simRel Schlicker et al. [2006] Yes Yes No No No MF prediction
SSDD Xu et al. [2013] No No Yes Yes No Correlation with EC, MF and sequence
SSM Couto et al. [2003] Yes Yes No Yes Yes Correlation with protein structure
TCSS Jain and Bader [2010] Yes Yes No No No PPI prediction
TopoICSim Ehsani and Drablos [2016] Yes No Yes Yes No Correlation with EC, MF and sequence
Wu Wu et al. [2005] No No Yes No No MF prediction
Wu-Palmer Wu and Palmer [1994] No Yes No Yes Yes Translation selection
XOA Sanfilippo et al. [2007] Depends on measure used Correlation with sequence
3.2 Evaluation of Semantic Similarity Measures
Given the variety of approaches and measures for SS, it becomes fundamental to evaluate how
well each measure captures the true similarity between two entities. However, the wide range of
domains and types of entities SS is applied to, makes it non-trivial to do so.
Based on the few comparative studies that exist, Pesquita [2017] identified the most successful
measures in different applications of GO-based SS (Table 3.3). However, in these studies, only
a few measures of interest for these particular applications are tested.
Although more classic measures of SS such as Resnik still provide top results in some settings,
there is a newer generation of measures that provide better results. These are a part of the new
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Table 3.2: Summary of Groupwise SSMs. Columns Class IC, Common Ancestor (MICA), All
Common Ancestors (ACA), Path Length, and Class Depth refer to the different features of
SSMs. Column Evaluation Technique describes the context in which each similarity measure
was tested.
Name Reference Class IC MICA ACA
Path
Lenght
Class
Depth
Evaluation Technique
Aggregative approach Ferreira and Couto [2019] Depends on measure used Annotation prediction
Ali and Deane Ali and Deane [2009] No Yes No No No Function prediction
Cho Cho et al. [2007] Yes Yes No No No PPI prediction
Cosine Popescu et al. [2006] No No No No No Correlation with sequence
Czekanowski-Dice Martin et al. [2004] No No Yes No No Gene Clustering
Dice Popescu et al. [2006] No No Yes No No Correlation with sequence
FMS Wu et al. [2005] Yes No No No No MF Prediction
ICOR Chen et al. [2012] Yes No Yes No No Correlation with EC, MF and sequence
Integrative approach Ferreira and Couto [2019] Depends on measure used Annotation prediction
IntelliGO Benabderrahmane et al. [2010] Yes Yes No Yes Yes Inter-set cohesion
Jaccard Popescu et al. [2006] No No Yes No No Correlation with sequence
Kappa statistics Huang et al. [2007] No No Yes No No Gene functional enrichment
NTO Mistry and Pavlidis [2008] No No Yes No No Correlation with sequence
PL Al-Mubaid and Nagar [2008] No No No Yes No Gene Clustering
simGIC Pesquita et al. [2008] Yes No Yes No No Correlation with sequence
simLP Gentleman et al. [2004] No Yes No No Yes Gene distance
simNLP Ye et al. [2005] No Yes No No Yes MF prediction
simUI Gentleman et al. [2004] No No Yes No No Gene Distance
SSA Sheehan et al. [2008] Yes Yes Depends on measure used Gene Clustering
SORA Teng et al. [2013] Yes No Yes No Yes Correlation with EC, MF and sequence
TO Lee et al. [2004] No No Yes No No Gene Clustering
TAS Yu et al. [2007] No Yes No No No Gene functional enrichment
Weighted cosine Chabalier et al. [2007] Yes No No No No Prediction of functional networks
WJ Popescu et al. [2006] Yes No Yes No No Correlation with sequence
Table 3.3: Most successful measures in different applications of GO-based SS.
Standard Best Measure
Sequence similarity SSDD, SimGIC, HRSS
Pfam similarity SORA, SSDD, SimGIC
EC similarity SSDD, HRSS, SORA
Expression similarity TCSS, SimGIC, SimIC, BMA (Resnik)
Protein–protein interaction TCSS, SimIC, Max (Resnik)
wave of more complex structural-based measures, such as SSDD, SORA and TCSS, that are
now on the lead.
Some semantic web related applications have turned to crowd-sourcing (e.g., in ontology
matching (Cheatham and Hitzler [2014]) and in verification of relations (Mortensen et al.
[2013])), which brings with it a series of new challenges. The evaluation task is highly dependent
on the ability to provide crowd-sourced workers with enough information to make a decision and
can be inherently biased towards a particular viewpoint of the domain or a particular use case.
This is of extreme relevance in biomedical SS, where two entities may be deemed similar across
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many different axis. For instance, two proteins can be compared via their molecular function,
expression, cellular localization, disease involvement, etc., making it difficult to select the best
angle of evaluation.
Most SSMs evaluations studies are data set based, where a new SSM is applied to all entities
or pairs in that data set and its performance (e.g. its correlation to some property, its F-measure
when used in a classification task or its p-value when used for the testing of an hypothesis) is
assessed, usually by comparison with those of other SSMs.
Building a gold standard data set to support SS evaluation is not trivial. Accomplishing this
manually is extremely time consuming and existing manual gold standards are very small com-
pared to the size of the ontologies they correspond to. For instance, Pedersen et al. [2007] created
a set of only 30 term pairs extracted from Unified Medical Language System (UMLS) Metathe-
saurus. The UMLS contains over one million biomedical concepts and five million concept
names, originating from more than 100 incorporated controlled vocabularies and classification
systems.
Many data sets have been used to evaluate KG-based SS. MateTee (Morales et al. [2017])
was evaluated both with data set of proteins annotated with the GO and with a data set based
on DBpedia entities of the type Person. AnnSim (Palma et al. [2015]) was also evaluated with
the same protein data set, but it also included additional evaluations based on disease similarity
and drug-target interaction prediction using other data sets.
Most of these studies are independent, meaning their results are not directly comparable,
and since they do not provide the necessary KG annotations for each data item, that are likely
to change over time, a fair and unbiased comparison between different tools would need to be
run with the exact versions of the data.
Pesquita et al. [2009b] developed CESSM (Collaborative Evaluation of Semantic Similarity
Measures). CESSM is a webtool designed for the comparison and evaluation of new GO-based
SS measures against previously published ones, considering their relation to sequence, Pfam
(El-Gebali et al. [2018]) and Enzyme Commission (EC) (Bairoch [2000]) similarity. CESSM’s
data set is made up of pairs of well-characterized proteins, regrading their classes average IC
and existence of Pfam families and EC classification.
Figure 3.1 provides an example of the evaluations provided by CESSM: Pearson correlation
between the novel measure and a molecular function similarity proxy - sequence similarity (Fig-
ure 3.1a) and the comparison of the behavior of the novel and state- of-the-art measures against
sequence similarity (Figure 3.1b).
CESSM was released in 2009, updated in 2014 and since then been widely used by the com-
munity, being adopted to evaluate over 25 novel SSMs developed through different methods,
more recently common IC-based metrics (Paul and Anand [2018]), and based on vector rep-
resentations/graph embeddings (Zhong et al. [2019]). CESSM was built as web-based tool to
support the automatic comparison against the benchmark data. Over time some limitations
of its use were identified: users looking to perform iterative evaluations were limited by access
through a graphical user interface; users were unable to calculate other metrics of performance
not supported by the tool; users were limited to a single ontology (GO) and a single functional
perspective given by the Pfam and EC proxies which focus on molecular function similarity.
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(a) Sequence similarity plot against the
novel measure.
(b) Averaged sequence similarity plot
against several SSMs.
Figure 3.1: Example of CESSM plot results
Despite its limitations, CESSM’s methodology for evaluation of SSMs shows effectiveness, since
all works developed with the same data are directly comparable, and its data set can be used
for other tasks than the evaluation techniques of SSMs supported by the tool (Liu et al. [2018]).
Although not directly related to biomedical SS, there are related contributions in the area of
benchmark data for link prediction (Bordes et al. [2013]; Socher et al. [2013]) and classification
in knowledge graphs (Ristoski et al. [2016]). KG-based SS can be applied in these contexts, but
these benchmark data sets do not support a direct evaluation of SSMs.
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Chapter 4
Methodology
This chapter presents an overview of the developed methodology for the creation of the bench-
mark and its use in the evaluation of SSMs.
The developed benchmark is composed of data sets and automated SS evaluation methods.
The first step, and the most important one, is defining the scope of each data set and what
measures of biological similarity will be used for the evaluation of SSMs. Only then can the
benchmark data sets and evaluation techniques be built around them. In this dissertation,
a general methodology for the construction of benchmark was developed. This methodology
follows four basic steps:
1. Definition of criteria for entity selection;
2. Definition of criteria for pair formation;
3. Computation of similarity measures for each pair of entities;
4. Development of automatic similarity measures evaluation techniques.
Figure 4.1 represents an overview of the basic methodology for the development of the
benchmark, with special focus on the development of the data sets.
Following the development of the data sets, automated evaluation methods should be built
to test the performance of the SSM. These methods should be based on the properties of the
data sets.
4.1 Definition of Criteria for Entity Selection
When selecting entities from the KG to the benchmark data sets, one should base the decision
on two features: the existence of of the necessary information to support the calculation of proxy
similarities, and the completion of the annotation of the entities.
Since these data sets will support proxy-based evaluation of SSMs, the first, and most im-
portant, criteria for the selection of entities is the existence of the necessary information for the
calculation of these proxies. Without that information, a proxy-based evaluation of the SSM
calculation would be impossible. For instance, let us imagine two orthologous proteins, A and
B. These two proteins are inferred to be descended from the same ancestral sequence separated
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Figure 4.1: Overview of the methodology steps for the development of benchmark.
by a speciation event, thus they share high sequence and function similarity. However, if the
sequence information for one of these proteins is not available, we can not calculate sequence
similarity and assess if the SSM value is consistent with the other representations of similarity.
Additionally, the annotations of these entities, namely their number and the ontology level
they are placed on, are also relevant for the SSM performance. Shallow annotations will influence
the SS results for the pairs of entities (Pesquita [2017]). Ignoring the specialization level of the
classes in the annotation can result in SS results that are inconsistent with human perception.
Thus, entities should be well described with classes from the ontology that contextualizes the
KG they are represented in, in order to avoid unrealistic SS values.
On the other hand, the number of annotations an entity carries can also impact SS calcu-
lation. For instance, an entity described with only one class is most likely to under perform in
pairwise SS approaches, as only that class will be compared against all the classes describing
the other entity.
Figure 4.2 compares the impact of different levels of ontology description in SS. Let us
imagine the same two analogous proteins, A and B. We know that due to their common ancestry,
they share the same functions. However, a poor annotation description will result in unrealistic
SS values, when compared to the other similarity representations (e.g. sequence similarity). In
panel 4.2a Protein B is shallowly annotated, SS is almost null. In panel 4.2b Protein B is under
annotated, SS is low. Finally, in panel 4.2c Protein B is properly described and the SS value is
accurate.
In sum, candidate entities for the benchmark data sets should have their meaning well
captured through ontology annotations. Other levels of annotation completion could also be
explored. These would provide a new axis of evaluation of SSMs, that of evaluating the impact
of the level of annotation completion in the ability of a measure to capture similarity between
entities. However, this is out of scope for this dissertation and will not be considered.
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Figure 4.2: Different levels of annotation descriptions and its impact on SS calculation. White-
filled circles are common classes between the two proteins, blue-filled circles are classes that only
annotate Protein A, and orange-filled circles are classes that only annotate Protein B.
4.2 Definition of Criteria for Pair Formation
The selected entities are then combined to form pairs. These pairs will make up the benchmark
data sets and be the basis for the calculation of SS. Thus, their selection can not be done
randomly. Entity pairs, as a whole, must provide a cross-section of the pairs of entities of each
species, while being representative of similarity values and excluding overlapping cases.
4.3 Computation of Similarity
In the last step of the development of the benchmark data sets SS and proxy similarity mea-
sures are calculated for each pair generated in the previous step. The SSMs used should be
representative of different types of approaches and well accepted in the community, while the
similarity proxies should be based on the properties of the entities so that they can, ultimately,
be used for the evaluation of SSMs. These proxy measures should be selected attending to the
selected KG characteristics, i.e. if the entities are diseases, proxy similarity cannot be sequence
similarity but rather involved genes.
These first three steps, ensure the development of data sets that respect the criteria for
quality benchmark data sets, namely relevance, representativeness and non-redundancy, through
the constraints in the selection of entities, pairs and similarity measures.
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4.4 Automated Evaluation Methods
In the last step of the construction of the benchmark, automated evaluation methods are de-
veloped. These methods should evaluate SSMs through their relation to the similarity proxies
selected in the development of the benchmark data sets.
The steps for the evaluation of SSMs using the benchmark are as follows:
1. Selection of SSM and benchmark data sets;
2. Calculating the selected SSM for all the pairs in the chosen data sets;
3. Evaluating the SSM performance, by performing the same testes for the new measure and
the state-of-the-art SSMs.
To do so, different evaluation methods can be developed, based on the type of similarity
proxies the data set holds. Figure 4.3 shows examples of evaluation methods the SSM can
undergo based on different types of similarity proxies.
Proxy 1
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Class B
…
Proxy 2
float
float
…
Similarity
proxies
Entity A Entity B
State of
the art
SSM
URI URI float
URI URI float
… … …
Benchmark
data set
Evaluation
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State of the
art SSM
Test SSM
SSM Proxy 1 Proxy 2
State of the art
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Test SSM
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Benchmark
tests
Test SSM
float
float
…
New 
measure
Figure 4.3: Examples of automated evaluation methods supported by the benchmark data sets. A)
SS-based classification evaluation B) Proxy-based correlation calculation.
The SSM under evaluation and the state-of-the-art SSMs available in the benchmark data
sets, must always be subjected to the same tests, so that their performance can be directly
comparable and any relevant findings made publicly available.
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Building the Benchmark
This chapter describes the application of the methodology presented in Chapter 4 to the creation
of a benchmark for SSMs in the biomedical domain, based on benchmark data sets. For the
construction of the data sets, two KGs were selected: proteins annotated with the GO and
human genes annotated with the HPO. Three sets of benchmark data sets resulted from this:
PPI data sets, molecular function (MF) data sets and gene-phenotypes (GP) data sets. PPI and
MF data sets are made up of protein pairs, while the GP data set is composed of gene pairs.
Adequate evaluation methods for each group of data sets were also developed under the scope
of the creation of this benchmark. The development of this resource followed the FAIR Guiding
Principles for scientific data management and stewardship.
5.1 Gene Ontology-based Benchmark data sets
5.1.1 The Gene Ontology Knowledge Graph
The GO is the most successful case of the use of an ontology in biomedical research and it is used
for the annotation of gene products. GO is a directed acyclic graph that covers three distinct
aspects of gene function: MF, Cellular Component (CC) and Biological Process (BP). The MF
sub-ontology describes the gene product’s role at the molecular level, CC describes the cellular
location of a gene product’s activity and BP the larger biological program to which a gene’s MF
contributes (Ashburner et al. [2000]). The majority of gene products are proteins, and here on
after will refer solely to proteins as the instances described by the GO.
The Gene Ontology Annotation (GOA) is a project that aims to provide assignments of
GO classes to proteins of any species, i.e., the semantic annotation of the proteins (Huntley
et al. [2014]). The annotations provide a standardized way to describe the regular activity of
proteins, and make them directly comparable with SSMs. The classes selected to annotate a
protein must always be the most specific classes in the ontology that best describe the entity’s
function according to available evidence because, due to the hierarchical structure of the GO,
a gene product that is annotated with any GO class is also annotated with all its ancestors.
Moreover, annotations are are a snapshot of the knowledge about an entity at a certain point
in time, meaning they can change over time, to reflect changes in knowledge and/or changes in
the ontology.
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The integration of GO with the GOA graph results in a KG where the instances are proteins
that are linked to GO via their annotations. Figure 2.3 shows an example of the use of GO to
annotate a gene product, the protein P19367. Each annotation is supported by an GO Evidence
Codes from the Evidence and Conclusions Ontology and a reference.
5.1.2 Proxies of Protein Similarity
For the protein data sets, three proxies of protein similarity: sequence similarity, MF similarity,
and PPI. These measures capture different aspects of protein similarity and are typically used
for the evaluation of SSMs, usually by correlation assessment (in the case of MF and sequence
similarity) or evaluation of the predictive power of SS (in the case of PPI) (Pesquita [2017]).
Protein sequence similarity measures the relationship between two sequences and it estab-
lishes the likelihood for sequence homology. Sequence similarity (simseq) was calculated through
the relative reciprocal BLAST score (RRBS) (Pesquita et al. [2008]), given by
RRBS(A,B) =
BLASTbitscore(A,B) +BLASTbitscore(B,A)
BLASTbitscore(A,A) +BLASTbitscore(B,B)
(5.1)
where A and B are two proteins.
The relationship between sequence similarity and SS is non-linear (Pesquita et al. [2008])
but becomes more relevant the higher the sequence similarity is (Ikram et al. [2018]). While
sequence similarity can be used to evaluate the performance of a SSM, it should not be the sole
evaluator in this task.
MF similarity is computed by comparing the functional regions (commonly termed domains)
that exist in each protein sequence. Protein functional domains are extracted from the Pfam ref-
erences contained in the UniProt database (El-Gebali et al. [2018]). Pfam similarity (simPfam)
is calculated as a Jaccard similarity, using the ratio between the number of families common to
proteins A and B and the total number of distinct families through proteins A and B, with
simPfam(A,B) =
|fA ∩ fB|
|fA ∪ fB|
(5.2)
where A and B are two proteins with the set of families fA and fB.
The more functional domains two proteins share, the more likely will be that their SS in the
GO is high, especially in the MF aspect since these domains are usually responsible by assigning
functions to proteins.
PPI has a binary representation: 1 if the proteins are reported to interact, 0 otherwise. Two
proteins are considered to be similar if they interact. PPIs have some correlation to SS in the
GO: if two proteins are co-localized in the cell and involved in the same large scale process, they
are most likely to interact and will share some GO classes in the BP and CC aspects. Both Sousa
et al. [2020] and Maetschke et al. [2011] show this to be true with PPI predicting approaches
that demonstrate higher predictive power when using classes from these two aspects. However,
two proteins can be very similar through different lenses (for instance, having high sequence,
semantic or MF similarity), due to being orthologous proteins, but not interact.
The above mentioned similarity proxies were employed after the generation of pairs for the
data sets, according to the scope of each collection of data sets. Data sets in the MF collection
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employ only MF and sequence similarity, while data sets in the PPI collection employ PPI and
sequence similarity.
5.1.3 Selection of Pairs of Proteins for the Benchmark data sets
The protein benchmark data sets are constituted by pairs of proteins, each identified by their
UniprotKB Accession Number (Consortium [2018]), and annotated with classes from the GO.
The GO graph (dated October 2019) was collected from the website1 in OBO format and contains
47,413 ontology classes. GO annotations were downloaded from the GOA2 database for four
species in Gene Association File (GAF) 2.1 format. The selected species were D. melanogaster,
E. coli, H. sapiens and S. cerevisiae due to being highly studied organisms with a large number
of annotations in each species GOA graphs. All GOA graphs are dated September 2019, except
E. coli dated July 2019. The species GOA graphs were made up of 12,490 D. melanogaster,
5,341 E. coli, 19,464 H. sapiens and 6,048 S. cerevisiae proteins, respectively, and their GO
annotations. Information for the calculation of the similarity proxies, namely Pfam families and
protein sequence was retrieved from each protein’s UniprotKB3 entry.
In GO SS, not only is the depth of the GO classes an important feature, as previously
exposed, as is the breadth of annotations within the three GO aspects. This is relevant not only
because measures may wish to handle the aspects differently, but also because each sub-ontology
describes an important functional aspect of the semantic characterization of a gene product,
and its characterization is only complete when including classes from the three aspects. For
instance, two proteins sharing a specific CC, will share a GO class with high IC. However, being
co-localized is not feature enough to determine if these two proteins are, in fact, similar, because
they can play different roles in that compartment and in the organism as a whole. This analysis
is parallel to the other GO aspects: two proteins can perform the same MF in different cellular
compartments and contribute with that function to different biological processes or they can be a
part of the same BP and not contribute with the same function or perform it in the same cellular
structure. If only one semantic aspect of the gene products is captured, the characterization of
the entity will be incomplete and can lead to a misleading similarity assessment between these
two proteins. Thus, full coverage of the GO aspects is crucial in choosing the entities.
Given the importance of both depth and breadth in the annotations, the proteins of each of
the four selected species were filtered according to the following criteria:
• One aspect: The proteins must have at least one annotation in each GO aspect, and in at
least one aspect there should be at least one leaf-class annotation.
• All aspects: The proteins must have at least one annotation in each GO aspect, and in
each aspect there should be at least one leaf-class annotation.
This ensures that all proteins are sufficiently annotated to support SS calculations in either
one or all aspects of GO. These criteria also result in all proteins in the All aspects data set
being included in the One aspect as well.
1http://geneontology.org/
2https://www.ebi.ac.uk/GOA/downloads
3https://www.uniprot.org/
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For the creation of the PPI data sets, a set of well-known benchmark PPI data sets were
used to extract interacting and non-interacting pairs. These data sets comprise pairs of proteins
with information about their interaction. Their original publication references and species are
presented in table 5.1.
Table 5.1: Benchmark PPI data sets used to select protein pairs for the PPI data sets with
original publication reference and protein’s species.
Data set Original Publication Species
STRING-SC Maetschke et al. [2011] S. cerevisiae
STRING-HS Maetschke et al. [2011] H. sapiens
STRING-EC Maetschke et al. [2011] E. coli
STRING-DM Maetschke et al. [2011] D. melanogaster
DIP-HS Jain and Bader [2010] H. sapiens
BIND-SC Ben-Hur and Noble [2005] S. cerevisiae
DIP/MIPS-SC Ben-Hur and Noble [2005] S. cerevisiae
GRID/HPRD-bal-HS Yu et al. [2010] H. sapiens
GRID/HPRD-unbal-HS Yu et al. [2010] H. sapiens
The pairs in which both proteins met the required criteria were then grouped by species (D.
melanogaster, E. coli, H. sapiens and S. cerevisiae), excluding all existing duplicate pairs. Two
additional data sets, joining all the pairs from these data sets at the same level of annotation
completion, were created. For all the pairs in these data sets, the corresponding similarity
proxies (PPI and sequence similarity) were calculated.
For the creation of the MF benchmark data sets, species-specific data sets (D. melanogaster,
E. coli, H. sapiens and S. cerevisiae) were created. Since MF similarity is based on Pfam
assignments to proteins, proteins in these data sets should also have, at least, one domain
identified in the Pfam database, which further filters down the number of eligible proteins.
Pairs of proteins were randomly generated ensuring roughly the same number of pairs with
null and total Pfam family identity. Two additional data sets, joining all the pairs from the these
data sets at the same level of annotation completion, were created. For all the pairs in these
data sets, the corresponding similarity proxies (MF and sequence similarity) were calculated.
5.2 Human Phenotype Ontology-based benchmark data set
5.2.1 Human Phenotype Ontology Knowledge Graph
The HPO provides comprehensive bioinformatic resources for the analysis of human diseases
and phenotypes (Köhler et al. [2018]). It is organized as independent subontologies that cover
different categories: “Phenotypic Abnormality” contains descriptions of clinical abnormalities,
“Mode of Inheritance”, “Frequency” and “Clinical Course” describe the relation between patients
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or diseases and their symptoms, and “Clinical Modifier” is designed to characterize and specify
the phenotypic abnormalities defined in the “Phenotypic Abnormality” subontology (Köhler
et al. [2018]). The HPO has been used to integrate sequencing data from multiple biotech
centres to identify patients with mutations in the same gene and comparable phenotypes, to
record detailed clinical phenotypes of patients with rare inherited disorders, to annotate clinical
cases with standard phenotype variants in order to cluster phenotypically overlapping patients,
and finally to increase interoperability between clinical laboratories (Köhler et al. [2018]). The
HPO can be used to annotate both patients, diseases or human genes. In the latter case, all
phenotype classes associated with any disease that is associated with variants in a gene are
assigned to that gene. An example of this is shown in Figure 5.1.
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Figure 5.1: Sub-graph of the HPO KG formed by a human gene (CLPP) and HPO classes. For this gene,
the classes that best describe it are chosen for its annotation.
5.2.2 Proxies of Gene Similarity
For the gene data set, the proxy similarity is based on OMIM’s Phenotypic Series (PS) (Amberger
et al. [2014]), which group identical or similar phenotypes involved in the same disorder. Up to
November 2019, OMIM had 464 different PS comprised of 3,777 phenotypes. Information on
how genes relate to PS was retrieved from OMIM4.
PS similarity (simPS) is defined as the ratio between the number of PS common to genes A
and B and the total number of distinct PS through genes A and B, with
simPS(A,B) =
|PSA ∩ PSB|
|PSA ∪ PSB|
(5.3)
4https://www.omim.org/phenotypicSeriesTitles/all
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where A and B are two genes with the set of PS PSA and PSB, respectively.
Similarly to simPfam in the MF protein data sets, simPs correlates to SS because the more
PS two genes are associated with, the more likely it is that they share HPO classes in the
“Phenotypic Abnormality” subontology, since PS are a set of similar phenotypes.
5.2.3 Selection of Pairs of Genes for the Benchmark data set
The GP benchmark data set is constituted by genes, identified by their Entrez Gene Code, and
annotated with classes from the HPO. The HPO graph (dated November 2019) was collected
from the HPO website5 in OBO format and contains 18,221 ontology classes. HPO annotations
were downloaded from the HPO website in a Tab-separated Values (TSV) file (dated November
2019). These annotations link the genes with the HPO classes which best describe the disease
in which the genes are proved to play a role. The used KG was made up of 4,293 human genes
and its annotations to the HPO. Information on how genes relate to Phenotypic Series (PS)
was retrieved from Online Mendelian Inheritance in Man (OMIM)6 in TSV format.
For the creation of the GP benchmark data set, all human genes meeting the following
criteria were considered:
1. The gene must be annotated with at least three classes in the HPO subontology “Pheno-
typic Abnormality”;
2. The gene must have a link with at least one phenotype in any PS, and the mechanism
behind that link must be known.
After selecting the eligible entities, pairs of genes were generated to ensure a data set with
the same number of pairs of genes with null, not-null and full PS similarity.
5.3 Semantic Similarity Calculation
For all data set pairs, different SSMs were calculated. Each of the selected SSM is a combination
of two approaches: the approach used to calculate the IC of an annotating class (ICSeco or
ICResnik) and the IC-based approach used to calculate the similarity between the KG entities
(simGIC or BMA). These approaches for IC-based entity similarity were selected because both
simGIC and BMA are high-performing classical measures of SS and still widely accepted within
the research community, in spite of the new wave of structural-based measures (see Table 3.3).
ICSeco, proposed by Seco et al. [2004], is an intrinsic approach based on the number of direct
and indirect children by class c and is given by
ICSeco(c) = 1−
log[hypo(c) + 1]
log[maxnodes] (5.4)
where hypo(c) is the number of direct and indirect children from class c (including class c) and
maxnodes is the total number of classes in the ontology.
5https://hpo.jax.org/
6https://www.omim.org/phenotypicSeriesTitles/all
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ICResnik is a corpus-based/extrinsic approach proposed by Resnik [1995] and based on the
number of entities annotated with class c in a KG, with
ICResnik(c) = − log p(c) (5.5)
where p(c) is the probability of annotation in the corpus.
A normalized version of ICResnik is given by
ICnorm(c) =
ICResnik(c)
logN (5.6)
with N being the total number of annotations.
Best Match Average (BMA) is a pairwise approach based on the pairwise measure in which
the similarity between two classes corresponds to the IC of their most informative common
ancestor (Resnik [1995]). In BMA only the best-matching class for each class in each set of
classes describing the individuals (i.e. the most similar) is considered to calculate BMA, given
by
BMA(A,B) =
∑
c1∈CA sim(c1, c2)
2|C(A)|
+
∑
c2∈CB sim(c2, c1)
2|C(B)|
(5.7)
where A and B are entities, C is the set of classes c each entity is described with and
sim(c1, c2) and sim(c2, c1) are the highest similarity values found for classes c1, c2. The similarity
between two classes can be found using Resnik’s similarity (Resnik [1995]) given by
sim(c1, c2) = max(IC(a)) : a ∈ A(c1) ∩A(c2) (5.8)
where a is a class in A(ci), the set of ancestors of ci.
SimGIC (Pesquita et al. [2007]) is a groupwise approach which resorts to the Jaccard simi-
larity, in which each class c is weighted by its IC. It is given by
simGIC(A,B) =
∑
c∈CA∩CB IC(c)∑
c∈CA∪CB IC(c)
(5.9)
where A and B are entities and C is the set of classes c each entity is annotated with.
By combining the approaches for entity similarity with the different ICs, we arrive at the
four state-of-the-art SSMs used for the data sets: BMAResnik, BMASeco, simGICResnik and
simGICSeco. These four measures are representative of the most successful approaches for
KG-based SS calculation.
SS between all data set entities was computed using the Semantics Measures Library Toolkit
(Harispe et al. [2013]), a Java Toolkit dedicated to semantic measures computation and analysis.
5.4 Automated Evaluation Methods
For the evaluation of SSMs using the benchmark data sets, automated evaluation methods were
developed based on the data sets characteristics.
Pearson Correlation Coefficient (PCC) is a measure of the linear correlation between two
variables X and Y. The PCC value ranged between -1 and 1, where -1 is total negative linear
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correlation, 0 is no linear correlation, and 1 is total positive linear correlation. It is usually
represented by r and is given by
rX,Y =
∑
i=1 n(xi − x̄)(yi − ȳ)√∑
i=1 n(xi − x̄)2
√∑
i=1 n(yi − ȳ)2
(5.10)
where n is the sample size, xi, yi are the individual sample points indexed with i and x̄ =
1
n
∑n
i=1 xi is the sample mean, analogously for ȳ.
In the context of evaluating SSMs with similarity proxies, xi and yi correspond to the set of
SS and proxy similarity values calculated for the n pairs of entities in the benchmark data sets.
The PCC for the test SSM should be compared with the PCC for the state-of-the-art SSMs in
the same data set, to assess the impact of the test SSM.
The correlation between two similarity measures can also be visualized in a scatter plot, by
assessing how well a linear function fits the data. Figure 5.2 shows an overview of rXY values
in different scatter plots.
𝒓𝑿𝒀 = −𝟏 −𝟏 < 𝒓𝑿𝒀 < 𝟎
𝒓𝑿𝒀 = 0 0 < 𝒓𝑿𝒀 < 𝟏 𝒓𝑿𝒀 = 1
Figure 5.2: Evolution of rXY value, through different scatter plot examples.
For the PPI data sets, SS-based PPI prediction can be employed. This is done by establishing
a similarity threshold: if a protein pair has a similarity above the threshold the proteins are
considered to interact, otherwise they’re not:
interaction(A,B) =
interact, if sim(A,B) ≥ tdon’t interact otherwise (5.11)
where sim(A,B) is the SS between two proteins A and B and t is the defined threshold for
similarity to determine if two proteins interact.
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For a given threshold, and knowing the true relation between N protein pairs, it is possible to
produce a confusion matrix. A confusion matrix allows for the visualization of the performance
of a supervised learning algorithm, in this case SS-based PPI prediction, as depicted in Table
5.2.
Table 5.2: Confusion matrix showing the performance of a supervised learning algorithm, based
on the number and type of correct and incorrect predicted labels: true positive (TP), false
positive (FP), true negative (TN) and false negative (FN).
True Interaction label
Positive Negative Total
Predicted Interaction
Positive TP FP TP + FP
Negative FN TN FN + TN
Total TP + FN FP + TN N
From the number of TP, FP, TN and FN, we can calculate precision, recall and F1score as
the evaluation scores for the prediction ability of a SSM.
In this case, precision is the fraction of pairs identified as interacting that actually interact
and is given by
precision =
TP
TP + FP
(5.12)
Recall measures the ratio of interacting pairs correctly identified as such and is given by
recall =
TP
TP + FN
(5.13)
F1score is the measure of the overall accuracy of the algorithm. It is calculated through the
harmonic mean of the precision and recall
F1score = 2
precision · recall
precision+ recall
(5.14)
Precision, recall and F1score values vary between 0 and 1, with 1 being the best possible
value, and 0 the worst. If the F1score reaches the value of 1, it means both precision and recall
have perfect scores. However, if any of these metrics is 0, F1score will also be 0 regardless of
the other metric score, meaning the algorithm under performs.
Precision-recall plots can be used to visualize evolution of the performance of the algorithm,
by varying the similarity threshold values and plotting the resulting precision and recall values.
To determine the best threshold of similarity for a given PPI prediction in a data set, 10-
fold cross validation was used. Cross validation is a machine-learning method to evaluate the
predictive skill of a classifying algorithm in a data set, as this SS-based PPI prediction algorithm.
In k-fold cross validation, the general procedure is to split the data set into k groups and
fit the model k times in k − 1 groups, each time leaving one group out as the test set, for the
evaluation of the model. In this SS-based PPI prediction algorithm, the procedure is as follows:
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1. Shuffle the data set randomly;
2. Split the data set into k groups, k should be an integer respecting the condition 1 < k ≤ n
where n is the data set size;
3. For each group:
(a) Take the group as the test set;
(b) Test different similarity threshold values in the remaining k − 1 groups;
(c) Select the threshold that outputs the highest F1score;
(d) Evaluate the performance of the selected similarity threshold on the test set.
4. Out of the k similarity thresholds tested in the test sets, select the median similarity
threshold.
The best threshold and correspondent precision, recall and F1score for all metrics (test and
state-of-the-art) can be compared in table or plot format. Alternatively, the performance of all
measures can be compared for a selected threshold, not determined by cross validation.
All these evaluation methods were implemented using different Python libraries: Scikit-learn
(Pedregosa et al. [2011]) was used to for the evaluation of the SS-based PPI prediction, the plots
were designed using Matplotlib (Hunter [2007]), and PCC was calculated resourcing to Pandas
(Virtanen et al. [2020]).
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Results and Discussion
This chapter presents the results of the methodology implementation led in Chapter 5, with a
discussion of the features, performance and availability of the resulting benchmark.
6.1 Benchmark performance
Applying the proposed methodology to the chosen KGs resulted in 21 different benchmark data
sets: ten PPI data sets, ten MF data sets and one GP data set, and associated evaluation
techniques. This section goes over the main features of the data sets and the results from linear
correlation evaluation techniques, displaying their validity for the proposed application.
The protein data sets comprise pairs of proteins from four different species (D. melanogaster,
E. coli, H. sapiens, and S. cerevisiae) that support the evaluation of GO-based SSMs, the main
application of SS in the biomedical domain, through comparison with relevant biological proper-
ties of the proteins (protein sequence, function and interactions). The complete characterization
(number of entities, pairs and annotation completeness) of these data sets is presented in tables
6.1 and 6.2.
Table 6.1: Species, number of proteins and pairs and level of annotation completion for all data
sets in the PPI collection.
One Aspect All Aspects
Species Proteins Pairs Proteins Pairs
D. melanogaster 481 397 335 270
E. coli 371 738 264 428
H. sapiens 7,644 44,677 7,149 42,204
S. cerevisiae 3,874 34,772 2,959 21,577
All 12,370 80,584 10,707 64,479
Tables 6.3 and 6.4 show PCC between all SSMs and the correspondent data sets similarity
proxies. For each data data set, the SSM with the higher PCC for each similarity proxy is
highlighted.
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Table 6.2: Species, number of proteins and pairs and level of annotation completion for all data
sets in the MF collection.
One Aspect All Aspects
Species Proteins Pairs Proteins Pairs
D. melanogaster 7,494 53,795 5,810 52,457
E. coli 1,250 4,623 748 1,813
H. sapiens 13,604 57,906 12,487 57,722
S. cerevisiae 4,783 42,192 3,660 30,747
All 27,131 158,512 22,705 142,736
Table 6.3: PCC between state-of-the-art SSMs (BMAResnik, BMASeco, simGICResnik and
simGICSeco) and sequence similarity (simSeq) and PPI for all data sets in the PPI collection.
SSM with the higher PCC with each similarity proxy is highlighted for each data set.
One Aspect All Aspects
Species Similarity measure simSeq PPI simSeq PPI
D. melanogaster
BMAResnik 0.401 0.834 0.432 0.795
BMASeco 0.424 0.812 0.464 0.784
simGICResnik 0.469 0.691 0.517 0.645
simGICSeco 0.483 0.693 0.526 0.647
E. coli
BMAResnik 0.199 0.700 0.146 0.678
BMASeco 0.234 0.711 0.185 0.693
simGICResnik 0.219 0.610 0.174 0.595
simGICSeco 0.230 0.626 0.182 0.609
H. sapiens
BMAResnik 0.400 0.510 0.406 0.510
BMASeco 0.385 0.519 0.393 0.520
simGICResnik 0.545 0.414 0.556 0.413
simGICSeco 0.535 0.422 0.546 0.421
S. cerevisiae
BMAResnik 0.240 0.666 0.268 0.642
BMASeco 0.236 0.654 0.269 0.633
simGICResnik 0.300 0.593 0.349 0.568
simGICSeco 0.300 0.593 0.351 0.568
All
BMAResnik 0.285 0.576 0.312 0.546
BMASeco 0.292 0.583 0.332 0.561
simGICResnik 0.372 0.504 0.435 0.474
simGICSeco 0.374 0.509 0.435 0.479
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In Table 6.3, positive correlation in all tests is observed. There is, in most cases, a lower
correlation to sequence similarity, as expected (Yu et al. [2010]), with the exception of the H.
sapiens data sets. BMA is shown to have higher correlation with PPI, while simGIC correlates
better to sequence similarity, with both properties being IC independent.
Table 6.4: PCC between state-of-the-art SSMs (BMAResnik, BMASeco, simGICResnik and
simGICSeco) and sequence similarity (simSeq) and MF similairty (simPfam) for all data sets in
the MF collection. SSM with the higher PCC with each similarity proxy is highlighted for each
data set.
One Aspect All Aspects
Species Similarity measure simSeq simPfam simSeq simPfam
D. melanogaster
BMAResnik 0.271 0.324 0.176 0.290
BMASeco 0.323 0.404 0.189 0.354
simGICResnik 0.493 0.576 0.438 0.609
simGICSeco 0.499 0.587 0.446 0.628
E. coli
BMAResnik 0.336 0.484 0.347 0.478
BMASeco 0.315 0.485 0.351 0.503
simGICResnik 0.340 0.357 0.394 0.367
simGICSeco 0.346 0.378 0.395 0.388
H. sapiens
BMAResnik 0.560 0.586 0.566 0.597
BMASeco 0.666 0.652 0.680 0.667
simGICResnik 0.719 0.598 0.729 0.606
simGICSeco 0.723 0.612 0.732 0.620
S. cerevisiae
BMAResnik 0.522 0.613 0.512 0.625
BMASeco 0.588 0.586 0.541 0.605
simGICResnik 0.663 0.541 0.662 0.527
simGICSeco 0.645 0.555 0.641 0.543
All
BMAResnik 0.431 0.505 0.388 0.483
BMASeco 0.521 0.537 0.490 0.524
simGICResnik 0.573 0.563 0.569 0.580
simGICSeco 0.569 0.576 0.566 0.560
In Table 6.4, positive correlations in all tests are also observed. Once more, simGIC correlates
better with sequence similarity than any BMA approach and, although this is not true for all
data sets, BMA approaches show better correlation with function similarity than simGIC.
The distribution of SSM across all the pairs in the data sets was assessed. For the protein
data sets, this was done resorting to each All species One Aspect data set, since it contains all
the pairs in that proxy’s data sets.
Figure 6.1 shows the distribution of all SSMs across all the pairs in the PPI data sets. One
should note that a large number of pairs show lower SSM. However, given that from a total of
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Figure 6.1: Distribution of all SSMs (BMAResnik, BMASeco, simGICResnik and simGICSeco)
values across all species’ protein pairs in the PPI data sets.
80,584 pairs of proteins in these data sets, 29,944 have positive interactions, it is expected that
the remaining 50,640 to have lower similarity, since they are not reported to interact. These data
sets are representative, because there are far more non-interacting proteins in the “real world”,
however, it is still important to include both positive and negative examples in a benchmark
data set.
Figure 6.2: Distribution of all SSMs (BMAResnik, BMASeco, simGICResnik and simGICSeco)
values across all species’ protein pairs in the MF data sets.
Figures 6.2 and 6.3 show the distribution of similarity across all the pairs in the MF data
sets. Analysing these figures, one can see they show a more evenly distributed semantic and MF
similarity throughout the pairs. This should be due to having an extra constraint in selecting
the pairs for the data sets, based on the MF similarity value, forcing the similarity to be more
evenly distributed. Thus, these data sets are representative in terms of values of the different
types of similarity measures, following a guideline of major importance for benchmark data sets.
Even though benchmark data sets should be non redundant, the overlap between data sets
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Figure 6.3: Distribution of SimPfam values across all species’ protein pairs in the MF data sets.
of the same species, but a different level of annotation completion, can be used to evaluate
the impact of more thoroughly described proteins in the performance of SSMs. Other levels
of annotation completion can be considered in the future, for a different and/or more broad
comparison of this impact.
The data sets in each level of annotation completion (All data sets) are a compilation of
all the protein pairs in each of the species-specific data sets. Even though, once more, there is
redundancy between these and the species-specific data sets, the All data sets are far larger and
can be used for a comparative evaluation of the scalability of the SSMs or SS-based approaches.
Regarding the GP data set, containing pairs of human genes, it supports the evaluation of
HPO-based gene SSMs through the role of genes in similar phenotypic disorders. This data set
has 12,000 pairs of genes, for a total of 2,026 different gene throughout.
Table 6.5 shows PCC between all SSM and simPS . The SSM with the higher PCC is
highlighted.
Table 6.5: PCC between simPS and state-of-the-art SSMs (BMAResnik, BMASeco,
simGICResnik and simGICSeco) for the Gene-Phenotypes data set.
Pearsons correlation coefficient
BMAResnik 0.572
BMASeco 0.590
simGICResnik 0.478
simGICSeco 0.482
The SSM that best correlates to simPS is BMASeco, however the PCC value for this SSM
is similar to those of BMAResnik and both simGIC approaches, all showing positive correlation
between the measures.
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Figure 6.4: Distribution of all SSMs (BMAResnik, BMASeco, simGICResnik and simGICSeco)
values across all the pairs in the GP data sets.
Figure 6.5: Distribution of simPS values across all the pairs in the GP data sets.
Figures 6.4 and 6.5 show the distribution of similarity across all the pairs in this data set.
Similarly to the MF data sets, and due to the same reasons, similarity, both semantic and PS, is
fairly distributed throughout the pairs. This means that the data set is representative in terms
of values of the different types of similarity measures, which means that it is a good candidate
for a SSM evaluation.
6.2 Benchmark availability and usage
This section describes the steps in the usage of the benchmark and it also has some notes on its
availability for the research community.
The evaluation of SSMs using the benchmark should follow the steps presented in Figure 4.3.
After selecting the measure to evaluate, the SS between the pairs of entities in the chosen data
sets must be assessed using that SSM and evaluated by benchmarking its performance against
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the state-of-the-art SSMs. The benchmark supports different evaluation methods, depending
on the similarity proxies available for the used data sets. Table 6.6 shows an overview of the
evaluation methods supported for each type of similarity proxy.
Table 6.6: Supported evaluation techniques by each similarity proxy.
Similarity Proxy
Pearson’s correlation
coefficient
calculation
Correlation plotting
Classification
performance
evaluation
simSeq   ×
simPfam   ×
PPI  × 
simPS   ×
The benchmark sustains a simple evaluation technique, namely the computation and visual-
ization of PCC, but also a more complex one, the PPI prediction evaluation. These are simple
evaluation tasks but are relevant for the evaluation of the performance of SSMs and often used
when doing so.
The evaluation methods were gathered in an interactive Jupyter Notebook that compiles all
the evaluation methods presented in Table 6.6 with a small tutorial on how to perform each
evaluation for each data set type. Figure 6.6 shows a screenshot of the introductory section of
the Jupyter Notebook and Figure 6.7 shows the results of the evaluation of two arbitrary SSMs
(Measure 1 and Measure 2) using a PPI data set.
Figure 6.6: Introductory section of the Jupyter Notebook, showing the table of contents and
necessary Python libraries for the Notebook use.
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(a) Correlation of the SSMs with similarity proxies.
(b) Assessment of the best threshold for each SSM for PPI prediction
using cross-validation and Precision-Recall plot.
(c) Assessment of PPI prediction ability of the SSMs at a given threshold
for SS.
Figure 6.7: Example of the results produced by the Jupyter Notebook when evaluating two
arbitrary measures (Measure 1 and Measure 2) using a PPI data set.
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The 21 data sets and the developed Jupyter Notebook were made publicly available to the
research community1. In addition, all the data that was used to compute the SS for all data
sets is made available in two different formats (1) Separate files for the ontologies and the
annotations files used (2) KGs, in OWL format, containing both the ontology and the instances
(divided by species). This allows for a direct comparison with the pre-computed SSMs in the
data sets, as well as facilitates the direct comparison between different SSM evaluation works
that use this resource, without needing to implement and/or compute the results. For this
reason, the benchmark will purposefully remain static for a few years, following the approach
used by CESSM (Pesquita et al. [2009b]), released in 2009 and updated in 2014.
The availability and accessibility of this resource promotes good practice in data management
and publication, by accounting for reusability. This ensures that the main goal of this benchmark
is achieved, by providing data and tools for the interoperable research of SS-based applications
and evaluation, and make these studies directly comparable. This means that the benchmark is
in line with the FAIR guiding principles.
6.3 Discussion
A big issue in the evaluation of SSMs is the diversity in the studies employed to do so. SSMs
are usually tested in a small and controlled set of data, developed for that study alone. This
unsystematic assessment practice can lead to biases in the published results, especially if not
compared with those of the state-of-the-art SSMs in the same conditions, i.e. using the exact
same version of the KG and the same entity pairs. Moreover, not employing a common strategy
or, at least, the same data, makes the results from these studies not directly comparable across
them.
This benchmark aimed at tackling these issues by providing data sets with pairs of entities
of different species, annotated with different ontologies and providing a combination of different
similarity proxies and multiple state-of-the-art SSMs. In fact, the benchmark represents an
evolution compared with the previous efforts in this area, both in terms of the size and diversity
of the data employed. This can be seen in Table 6.7, when comparing these data sets to both
updates of CESSM (Pesquita et al. [2009b]).
Table 6.7: Comparison between CESSM and KG Sim Benchmark in terms of number of entities,
pairs, ontologies and species.
Resource CESSM 2009 CESSM 2014 KG Sim Benchmark
Entities 1,039 1,626 30,831
Pairs 13,430 22,302 249,875
Ontologies GO GO GO & HPO
Species Non-specific 4
Using multiple KGs benefits benchmark utility due to the different structure and context of
1https://github.com/liseda-lab/kgsim-benchmark
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these graphs. Although both are biomedical ontologies, the GO provides a structured vocabulary
for the annotation of gene products regarding their role in the cell and organism, and the HPO
is an ontology of medically relevant phenotypes. The difference in the structure of these two
ontologies can also play a role in the performance of the measure. The GO is divided in three
independent subontologies that capture different aspects of a gene product’s role in the cell, all
of them necessary for a full characterization of the gene product. The HPO, on the other hand
has five subontologies, but only the main one (“Phenotypic Abnormality”) was considered when
calculating the state-of-the art similarity for the HPO data set. Evaluating a SSM with these
two different KG could yield different results for the performance of the measure, due to the
highlighted differences between them. This suggests that testing the same SSM in differently
targeted KGs can be a good evaluator of its ability to generalize to different KGs, entity types
and applications.
In order to guarantee that the SSMs can capture the functional similarity between the
entities, their meaning must be well captured within the ontology context. This meant selecting
entities annotated with more specific ontology classes (classes with fewer child classes), as sharing
one, or more, of these classes will result in a higher and more significant SS between the two
entities. This was done in order to tackle the shallow annotation problem for SSMs, that results
in SS values that are inconsistent with human perception, due to shallowly described entities
(Pesquita [2017]).
However, there is still another feature that can impact SS results, the annotation length.
The annotations each entities carries can impact SS values. Annotations are not uniformly
distributed among entities: some entities are widely studied and are very well annotated, while
others are poorly described. This can hinder the performance of SSMs in tasks such as PPI
prediction (Jiang et al. [2014]). There is, additionally, a positive correlation between SS and
the number of annotations from a pair of entities, whereas as the difference in the number of
annotations between the entities increases, their SS can decrease (Kulmanov and Hoehndorf
[2017]).
Thus, it was non-trivial to establish the criteria for entity selection, to avoid both these
issues. The selected criteria established a minimum number of annotation per entity, but no
maximum number or threshold for annotation size difference. However, the selected entities are
well characterized with other biological data (e.g. sequence, functional domains, involvement
in diseases), which suggests that the entities and pairs in the data sets should have a balanced
number of annotations. Nonetheless, the data sets can be employed for studying the existence
of this effect in a new set of data sets, with the selected SSMs. Furthermore, the developed
methodology can be easily applied to generate benchmarks targeting different criteria for en-
tity pair selection, such as those based on annotation length, to produce tailored data sets to
investigate this specific issue.
The benchmark takes advantage of proxies of entity similarity for the evaluation of SSMs
as a device for determining functional similarity of two biomedical entities. The definition of
biological function similarity is ambiguous because its exact meaning varies based on the context
in which it is used (Friedberg [2006]). This bias is especially relevant when similarity is being
defined by domain experts. For instance, let us imagine two protein kinases. These are proteins
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that modify other proteins by adding a phosphate group to them. A biochemist could deem the
two proteins as very similar because they’re both kinases, therefore, they have the same function.
However, when analysing the two proteins from a physician’s perspective, they might be more
interested in the role these two proteins play in the whole-organism level. The two kinases may
be involved in different signaling pathways, and different mutations in this kinases might cause
different diseases. Thus, from a physiological point of view, the two kinases are dissimilar. Not
only is it unfeasible to ask domain experts to do this manual verification of similarity for every
pair of biological entities there is, due to the amount of data in these domains, their perception
will always be biased to their field of study or area of expertise.
Enter similarity proxies. These measures of similarity, despite still capturing only one func-
tional aspect of the entities at a time, bear two advantages: they rely on objective representa-
tions of the entities (e.g. gene sequence, protein structure, existence of PPI, metabolic pathways
affected by the disease) and calculate similarity using mathematical expressions or other algo-
rithms. Not only can these algorithms compare entities at a much faster rate than human
experts, they can quantify the result from that comparison, as opposed to a similar/dissimilar
assessment.
The benchmark supports the evaluation of SSMs based on four different similarity proxies:
protein sequence similarity, existence of PPIs, MF similarity and PS similarity. The first three
proxies are proxies for protein similarity and can be used to evaluate GO-based SSMs, whereas
the latter is a proxy for gene similarity, for the evaluation of HPO-based SSMs.
There was a bigger effort towards developing the evaluation methods for GO-based SSMs,
because GO is the most widely used ontology in the study of SSM and its applications. The
GO-based benchmark data sets can be divided by the similarity proxies employed in them. For
each of the data sets the combination of similarity proxies can either be (1) PPIs and sequence
similarity or (2) MF and sequence similarity. Sequence similarity is considered for both these
data sets because, not only can it be computed for any two proteins for which sequence is known,
and there is no restriction in the pairs of proteins for which it is computed, but also because
sequence similarity does not show a strong enough relation with SS (Ikram et al. [2018]) to be
used alone, as a sole evaluator of SSMs. As exposed in Chapter 5, PPI and MF are known to
have different relation with the GO aspects. While MF similarity is expected to correlate better
with more matching classes from the MF subontology, the existence of a PPI is more likely to be
in agreement with overlapping classes in the CC and BP subontologies. Thus, a SSM that has
a positive relation with both these proxies, is a SSM that does a good job in capturing entity
similarity, as it is capable of considering different aspects of it.
The HPO-based data set considers only one similarity proxy, PS similarity. This similarity
proxy can be seen as an evaluation of how well SS captures the probability of two genes being
involved in the same disorders.
Finally, the selected state-of-the-art SSMs, BMAResnik, BMASeco, simGICResnik and
simGICSeco, are classic approaches for SS made up of a combination of an approach to calculate
the IC of the ontology classes that describe the entities, and an approach for combining those
values of IC to achieve a value for the SS between the two entities. By combining the two
different-natured approaches of each component of a SSM we capture a full spectrum of successful
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approaches for the calculation of SS. This provides a broader term of comparison for the SSMs
tested using the benchmark, as opposed to providing the results using only one type of state-of-
the-art SSMs.
Through the analysis of Tables 6.3 and 6.4 simultaneously, it is possible to see that simGIC
is the measure with the best correlation with sequence similarity, in spite of the species, level of
annotation and the other similarity proxy considered (MF similarity or PPI). This is consistent
with other observations, where simGIC ranks in the top in terms of correlation with sequence
similarity (Wu et al. [2013]; Pesquita et al. [2008]). The correlation between SS and MF similarity
is overall better when using BMA, although being sometimes outperformed by simGIC. Most
research indicates a similar performance by both these methods in different data sets (Bible et al.
[2017]; Dutta et al. [2017]; Wu et al. [2013]). In terms of relation to PPIs, BMA outperforms
simGIC in all data sets. Once more, this was expected, following previous evaluation comparing
both measures (Jain and Bader [2010]). The Maximum approach is usually better than BMA
in this task because interacting proteins only need to share a CC or BP class for their similarity
to be biologically relevant for PPIs. Nonetheless, BMA still performs well and is used in more
SS-based applications, while the Maximum approach is unsuitable to assess global similarity
(Pesquita [2017]), thus the decision of using BMA instead of the Maximum approach. Finally,
Table 6.5 shows that PS similarity correlates well with all four SSMs used, its behaviour being
similar to that of MF similarity, probably due to being calculated using the same formula.
In sum, the state-of-the-art SSMs perform well in all correlation tests they were subjected
to, meaning these results are in line with other assessments made in the past.
The features of the benchmark data sets in here discussed, along with making the benchmark
easy to obtain and use, show that the benchmark follows the guidelines that should be considered
in building a trust-worthy benchmark.
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The diversity in applications for SS, especially when studying biological entities, has widely
boosted the development of new SSMs that formalize the notion of similarity in slightly different
ways and may disagree on what makes two entities similar or distinct. This variety in measures
for calculating SS, coupled with the diversity in applications that benefit from it, raises the need
to answer the question: “what is the best SSM for each application?”.
Since there is no gold standard for similarity between biological entities, because these are
very complex entities, one solution is to compare the SSMs to measures, or proxies, of biological
similarity, and assess how the SSMs capture the entities similarity from different lenses.
The goal of this dissertation was to develop a benchmark for SSMs in the biomedical domain,
that supports the large-scale evaluation of SSMs, by exploiting proxies for biomedical entity
similarity. The benchmark is made up of a collection of benchmark data sets and automated
evaluation techniques for SSMs. This was done by developing and applying a methodology for
the construction of benchmark data sets for KG based SS and fitting evaluation techniques,
supported by the features of the data sets and their underlying entities.
The methodology developed within this dissertation was applied to two KGs: proteins an-
notated with the GO and genes annotated with the HPO, and resulted in a benchmark made
up of a collection of 21 benchmark data sets and evaluation techniques that fit the data sets
characteristics.
Out of the 21 data sets, 20 are based on the GO KG, given it is the most successful case of
the use of an ontology in the biomedical domain and it supports the annotation of gene products
of different species. There are two major groups of data sets: one based on MF similarity and
another based on PPIs. These proxies of similarity capture the similarity of entities through
different lenses and can evaluate how well the different SSMs fit them. These data sets are also
divided by species and level of annotation completion. The diversity in these features among
the data sets can also have an impact in the performance of a SSM.
The HPO data set exploits the role of human genes in different phenotypic abnormalities.
This data set, along with the evaluation of SSMs, can also be used to evaluate the impact of SS
in the prediction of genes that play a role in the same diseases, since if PS similarity is not null,
the genes will be involved in, at least, one matching disorder.
The collection of data sets also represents a contribution in itself, since the data sets therein
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can be used for the employment of other SS-based approaches, as supervised/unsupervised
learning techniques. It also represents an evolution compared with the previous efforts in this
area, both in terms of the size and diversity of the data employed.
The benchmark supports the calculation of correlation between the different SSMs and the
similarity proxies of each data set. Additionally, for the PPI data sets, it also supports the
evaluation of the predictive power of SSMs when performing SS-based PPI prediction. The
benchmark data can also be used to evaluate the multiple components of a SSM, i.e., IC, class-
based similarity, and instance-based similarity approaches.
Overall, the benchmark follows the FAIR guiding principles for scientific data management
and stewardship. The data sets use the adequate URIs for all entities in the data sets and KG
data used, the benchmark is available and accessible for the use by the research community and,
by providing the relevant KG data used to produce the data set, its reusability is promoted and
encouraged. Ultimately, the goal of this benchmark is to lead to interoperability of the results
in the evaluation of SSM, for direct comparisons between different studies.
Despite being domain-specific, it is expected that this benchmark and collection of data
sets to also be useful beyond the biomedical domain. Similarity computation within KGs is a
fundamental building block of many semantic web applications ranging from data integration to
data mining, meaning the benchmark data sets can be used for the evaluation of SSMs developed
outside the biomedical domain.
7.1 Future Work
This dissertation presented a benchmark for the large scale evaluation of SSMs in the biomedical
domain. However, it can still be updated to improve the existing features or add new ones. In
the future, updates to the benchmark can include:
• Updates to the existing data sets: inclusion of other state-of-the-art SSMs, inclusion of new
similarity proxies and evaluation techniques, updated selection features for the entities, etc;
• Inclusion of data sets with pairs of entities annotated with different biomedical ontologies;
• Expansion of the GO data set collection: inclusion of pairs of proteins of other species,
inclusion of SS calculated under each aspect of GO to support other learning techniques,
etc.
• Expansion of the HPO data set collection: inclusion of data sets with pairs of human
diseases, to support the evaluation of SSM in the prediction of diagnosis for patients.
Furthermore, the general approach developed for the creation of the data sets is generalizable
to any domain where a similarity proxy can be created, making the development of analogous
benchmarks outside the biomedical domain a possibility.
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